© 2022 MJH Life Sciences and Drug Topics. All rights reserved.
© 2022 MJH Life Sciences™ and Drug Topics. All rights reserved.
September 21, 2022
A national study in Germany identified the baseline characteristics of patients with moderate-to-severe atopic dermatitis (AD) to understand how they are usually treated with Dupixent in the real world.
August 11, 2022
Patients with persistently controlled atopic dermatitis who had their doses reduced were able to maintain their low disease activity.
July 07, 2022
The increases had no impact on the efficacy of the drug and were rarely associated with symptoms or sequelae.
June 29, 2022
Certain problems related to health-related quality of life (HRQOL) became more common among patients with atopic dermatitis since the start of the COVID-19 pandemic.
May 25, 2022
Data gathered from an electronic medical record found the results in a real-world patient population with atopic dermatitis were consistent with those found in clinical trials.
February 08, 2022
President Biden is reviving the program he headed as vice president, with the goal of reducing the cancer mortality rate and improving the experience of patients and their loved ones.